YH008 is a potentially first-in-class anti-PD-1 x CD40 bispecific antibody for the treatment of solid tumors. YH008 activates CD40 while simultaneously inhibiting PD-1. Our pre-clinical data shows that YH008 has promising in vivo efficacy and superior safety. The results of in vitro and in vivo experiments show that the activation of the CD40 pathway by YH008 depends on the cross-linking effect of PD-1, avoiding non-specific activation outside the tumor microenvironment. It has received FDA IND clearance in December 2022.